Abstract
Type 2 diabetes (T2D) is a multifactorial condition whose greatest impact comes from its complications. Not only impaired glucose homeostasis, but also lipid alterations have a relevant role, with insulin derived mechanisms behind this milieu, i.e., glycemia and lipidemia. Thus, we hypothesized that a) distinct glucose and lipid profiles and b) sex differences, particularly in lipids patterns, may be used to identify subjects at higher risk to develop T2D.
The PREVADIAB2 study evaluated metabolic alterations after 5 years in subjects without T2D when participating to PREVADIAB1. Herein, 953 subjects from the PREVADIAB2 cohort were stratified using a hierarchical clustering algorithm, informed by HOMA-IR, IGI, fISR and fIC. The resulting clusters were profiled and the lipidome of a subset (n=488) was assessed by LC/MS-QTOF.
We identified four clusters, named according to their main metabolic features: Liver Sensitive (LS); Pancreas Glucose Sensitive (PGS); Insulin Deficient (ID); and Insulin Resistant (IR). These cluster metabolic patterns were similar between sexes. However, men and women had distinct parameters cut-offs and lipidomic profiles. Overall, women presented higher long chain ceramides. Nonetheless, men had higher ceramide to sphingomyelin ratio and higher lysophosphatidylcholine to phosphatidylcholine ratio. For both genders, the LS cluster had the most advantageous lipid profile, whereas the other clusters presented lipid specificities towards dysmetabolism. This work shows that clustering individuals by distinct insulin-related metabolic features and sex identifies different phenotypes with distinct lipidome profile, thus demonstrating the importance of placing diabetes in a broader context of metabolism beyond glucose.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by Foundation for Science and Technology (FCT, PTDC/MEC-MET/29314/2017, 2022.05764.PTDC, UIDB/Multi/04462/2020), by the European Commission Marie Skłodowska Curie Action H2020 (grant agreement n. 734719), by the FEDER funds through the COMPETE 2020 Program under the project BEST (ALT20-03-0247-FEDER-113469, LISBOA-01-0247-FEDER-113469) and by the Sociedade Portuguesa de Diabetologia.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of Associacao Protetora dos Diabeticos de Portugal (APDP-Diabetes Portugal) gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
